Azithromycin for Bronchial Asthma in Adults: An Effectiveness Trial

References

1. 1.↵
   1. Richeldi L,
   2. Ferrara G,
   3. Fabbri LM,
   4. Lasserson TJ,
   5. Gibson PG

   . Macrolides for chronic asthma. Cochrane Database Syst Rev 2005;(3):CD002997.
2. 2.↵
   1. Altenburg J,
   2. de Graaff CS,
   3. van der Werf TS,
   4. Boersma WG

   . Immunomodulatory effects of macrolide antibiotics - part 1: biological mechanisms. Respiration 2011;81:67–74.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Johnston SL,
   2. Martin RJ

   . Chlamydophila pneumoniae and Mycoplasma pneumoniae. A role in asthma pathogenesis? Am J Respir Crit Care Med 2005;172:1078–89.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Herland K,
   2. Akselsen J-P,
   3. Skjønsberg OH,
   4. Bjermer L

   . How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease? Respir Med 2005;99:11–9.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Travers J,
   2. Marsh S,
   3. Williams M,
   4. et al

   . External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax 2007;62:219–23.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Demoly P,
   2. Gueron B,
   3. Annunziata K,
   4. Adamek L,
   5. Walters RD

   . Update on asthma control in five European countries: results of a 2008 survey. Eur Respir Rev 2010;19:150–7.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   Global Initiative for Asthma (GINA) 2007. Global Strategy for Asthma Management and Prevention. Updated 2007. GINA Executive Committee, 92 pages.
8. 8.
   American Thoracic Society. Lung function testing: selection of reference values and interpretive strategies. Am J Resp Dis 1991;144:1202–18.

   OpenUrl
9. 9.
   1. Dekker FW,
   2. Schrier AC,
   3. Sterk PJ,
   4. Dijkman JH

   . Validity of peak expiratory flow measurement in assessing reversibility of airflow obstruction. Thorax 1992;47:162–6.

   OpenUrlAbstract/FREE Full Text
10. 10.
    1. Juniper EF,
    2. Buist AS,
    3. Cox FM,
    4. Ferrie PJ,
    5. King DR

    . Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 1999;115:1265–70.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.
    1. Juniper EF,
    2. O'Byrne PM,
    3. Guyatt GH,
    4. Ferrie PJ,
    5. King DR

    . Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902–7.

    OpenUrlAbstract/FREE Full Text
12. 12.
    1. Juniper EF,
    2. O'Byrne PM,
    3. Roberts JN

    . Measuring asthma control in group studies: do we need airway calibre and rescue beta2-agonist use? Respir Med 2001;95:319–23.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Hahn DL

    . An unanticipated effect of clinical trial registration. BMJ [serial online] Available from: http://www.bmj.com/content/325/7376/1314?tab=responses, 2007. Accessed April 27, 2012.
14. 14.↵
    1. Juniper EF,
    2. Guyatt GH,
    3. Willan A,
    4. Griffeth LE

    . Determining a minimal important change in a disease-specific quality of life instrument. J Clin Epidemiol 1994;47:81–7.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Peters SP,
    2. Kunselman SJ,
    3. Icitovic N,
    4. et al

    . Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010;363:1715–26.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Smith DH,
    2. Malone DC,
    3. Lawson KA,
    4. Okamoto LJ,
    5. Battista C,
    6. Saunders WB

    . A national estimate of the economic cost of asthma. Am J Resp Crit Care Med 1997;156:787–93.

    OpenUrlPubMedWeb of Science
17. 17.↵
    1. Shoji T,
    2. Yoshida S,
    3. Sakamoto H,
    4. Hasegawa H,
    5. Nakagawa H,
    6. Amayasu H

    . Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clin Exp Allergy 1999;29:950–6.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Amayasu H,
    2. Yoshida S,
    3. Ebana S,
    4. et al

    . Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 2000;84:594–8.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Black PN,
    2. Blasi F,
    3. Jenkins CR,
    4. et al

    . Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med 2001;164:536–41.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    1. Kraft M,
    2. Cassell GH,
    3. Pak J,
    4. Martin RJ

    . Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma. Effect of clarithromycin. Chest 2002;121:1782–8.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.↵
    1. Kostadima E,
    2. Tsiodras S,
    3. Alexopoulos EI,
    4. et al

    . Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur Respir J 2004;23:714–7.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Hahn DL,
    2. Plane MB,
    3. Mahdi OS,
    4. Byrne GI

    . Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clin Trials 2006;1:e11.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Piacentini GL,
    2. Peroni DG,
    3. Bodini A,
    4. et al

    . Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy Asthma Proc 2007;28:194–8.

    OpenUrlCrossRefPubMedWeb of Science
24. 24.↵
    1. Simpson JL,
    2. Powell H,
    3. Boyle MJ,
    4. Scott RJ,
    5. Gibson PG

    . Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008;177:148–55.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Strunk RC,
    2. Bacharier LB,
    3. Phillips BR,
    4. et al

    . Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. J Allergy Clin Immunol 2008;122:1138–44.

    OpenUrlCrossRefPubMedWeb of Science
26. 26.↵
    1. Sutherland ER,
    2. King TS,
    3. Icitovic N,
    4. et al

    . A trial of clarithromycin for the treatment of suboptimally controlled asthma. J Allergy Clin Immunol 2010;126:747–53.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. von Hertzen L,
    2. Vasankari T,
    3. Liippo K,
    4. Wahlström E,
    5. Puolakkainen M

    . Chlamydia pneumoniae and severity of asthma. Scand J Infect Dis 2002;34:22–7.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    1. Hahn DL,
    2. Golubjatnikov R

    . Smoking is a potential confounder of the Chlamydia pneumoniae-coronary artery disease association. Arterioscler Thromb 1992;12:945–7.

    OpenUrlAbstract/FREE Full Text
29. 29.↵
    1. Pasternak R,
    2. Huhtala H,
    3. Karjalainen J

    . Chlamydophila (Chlamydia) pneumoniae serology and asthma in adults: a longitudinal analysis. J All Clin Immunol 2005;116:1123–8.

    OpenUrlCrossRefPubMedWeb of Science
30. 30.↵
    1. Brandén E,
    2. Koyi H,
    3. Gnarpe H,
    4. Tornling G

    . Chronic Chlamydia pneumoniae infection is a risk factor for the development of COPD. Respir Med 2005;99:20–6.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Hahn DL

    . Infectious asthma: a reemerging clinical entity? J Fam Pract 1995;41:153–7.

    OpenUrlPubMed
32. 32.↵
    1. Grayston JT,
    2. Kronmal RA,
    3. Jackson LA,
    4. et al

    . Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005;352:1637–45.

    OpenUrlCrossRefPubMedWeb of Science
33. 33.↵
    1. O'Connor CM,
    2. Dunne MW,
    3. Pfeffer MA,
    4. et al

    . Azithomycin for the secondary prevention of coronary heart disease events: the WIZARD Study: a randomized controlled trial. JAMA 2003;290:1459–66.

    OpenUrlCrossRefPubMedWeb of Science
34. 34.↵
    1. Albert RK,
    2. Connett J,
    3. Bailey WC,
    4. et al

    . Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689–98.

    OpenUrlCrossRefPubMedWeb of Science
35. 35.↵
    1. Hahn DL

    . Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:2235–7.

    OpenUrlPubMed
36. 36.↵
    1. Schentag JJ,
    2. Ballow CH

    . Tissue-directed pharmacokinetics. Am J Med 1991;91:5S–11S.

    OpenUrlPubMed
37. 37.↵
    1. Ebell MH,
    2. Siwek J,
    3. Weiss BD,
    4. et al

    . Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract 2004;17:59–67.

    OpenUrlAbstract/FREE Full Text
38. 38.↵
    1. Hahn DL

    . Treatment of Chlamydia pneumoniae infection in adult asthma: a before-after trial. J Fam Pract 1995;41:345–51.

    OpenUrlPubMedWeb of Science
39. 39.↵
    1. Aronson N,
    2. Lefevre F,
    3. Piper M,
    4. et al

    . Management of chronic asthma. Evidence report/technology assessment number 44. AHRQ publication no. 01-E044. Rockville, MD: Agency for Healthcare Research and Quality; 2001.
40. 40.↵
    1. Tunis SR,
    2. Stryer DB,
    3. Clancy CM

    . Practical clinical trials. Increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003;290:1624–32.

    OpenUrlCrossRefPubMedWeb of Science
41. 41.↵
    1. Thorpe KE,
    2. Zwarenstein M,
    3. Oxman AD,
    4. et al

    . A pragmatic - explanatory continuum indicator summary (PREVIS): a tool to help trial designers. J Clin Epidemiol 2009;62:464–75.

    OpenUrlCrossRefPubMedWeb of Science
42. 42.↵
    1. Rollins DR,
    2. Beuther DA,
    3. Martin RJ

    . Update on infection and antibiotics in asthma. Curr Allergy Asthma Rep 2010;10:67–73.

    OpenUrlCrossRefPubMedWeb of Science